<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920117-0044</DOCNO><DOCID>920117-0044.</DOCID><HL>   Business Brief -- Genzyme Corp.:   IG Labs Pays Cash, Stock   To Purchase Genetic Design</HL><DATE>01/17/92</DATE><SO>WALL STREET JOURNAL (J), PAGE A7D</SO><CO>   GENZ IGLI</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL SUPPLIES, EYEGLASS MANUFACTURERS (MDS)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>MASSACHUSETTS (MA)NORTH CAROLINA (NC)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   Genzyme Corp.'s majority-owned IG Laboratories Inc.strengthened its position in genetic testing with thepurchase of closely held Genetic Design Inc., a Greensboro,N.C., testing lab, for $22.6 million in Genzyme stock and$750,000 in cash.   Genzyme, Cambridge, Mass., said IG Labs would issue 2.4million shares to Genzyme in exchange for 390,000 Genzymeshares to be used in the acquisition plus $11 million incash. The total value of Genzyme shares for the transactionwill remain constant, but the number of shares will beadjusted to reflect changes in the stock price.</LP><TEXT>   IG Labs will keep $5 million for working capital and use$6 million to pay some Genetic Design debt, making theeffective purchase price of Genetic Design about $29.3million.   Genzyme said the combined businesses of IG Labs andGenetic Design should generate revenue of $30 million in1992.   After the exchange of shares involved in the transaction,Genzyme's ownership in IG Labs will increase to 68% from 56%.</TEXT></DOC>